Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment.
We describe the case of a 64-year-old female patient with rheumatoid arthritis (RA), who presented with lymphoproliferative disease (LPD) soon after the administration of etanercept, and regressed very shortly after the withdrawal of it. The occurrence was also associated with the Epstein-Barr virus (EBV) infection. The case of our patient may provide the evidence that etanercept plays an etiologic role in LPD in patients with RA.
Park
Sung-Hoon
SH
Department of Internal Medicine, Catholic University of Daegu School of Medicine, 3056-6 Namgu Daemyung 4-Dong, 705-718 Daegu, South Korea.
Kim
Chae-Gi
CG
Kim
Ji-Young
JY
Choe
Jung-Yoon
JY
D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008198:Lymph Nodes / Q000473:pathology; D008232:Lymphoproliferative Disorders / Q000139:chemically induced* / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept